Millson T, Hackbarth D, Bernard HL. A demonstration project on the impact of safety culture on infection control practices in Hemodialysis. Am J Infect Control. 2019;47(9):1122–9.
Salzer WL. Peritoneal dialysis-related peritonitis: challenges and solutions. Int J Nephrol Renovasc Dis. 2018;11:173–86.
Sarnak MJ, Jaber BL. Mortality caused by sepsis in patients with end-stage renal disease compared with the general population. Kidney Int. 2000;58(4):1758–64.
Lu R, Estremadoyro C, Chen X, Zhu M, Ribeiro LC, Yan Y, et al. Hemodialysis versus peritoneal dialysis: an observational study in two international centers. Int J Artif Organs. 2018;41(1):58–65.
Ridão Curty NF, da Silva Martins LF, Sanches Ito CA, Schafranski M, Brites DA, Busato CR. Morbimortality study of infection in patients undergoing different types of Dialysis in a renal replacement therapy center. Braz J Infect Dis. 2014;18(3):281–6.
Laurin LP, Harrak H, Elftouh N, Ouimet D, Vallee M, Lafrance JP. Outcomes of Infection-Related hospitalization according to dialysis modality. Clin J Am Soc Nephrol. 2015;10(5):817–24.
Johnson DW, Dent H, Hawley CM, McDonald SP, Rosman JB, Brown FG, Bannister KM, Wiggins KJ. Associations of Dialysis modality and infectious mortality in incident dialysis patients in Australia and New Zealand. Am J Kidney Dis. 2009;53(2):290–7.
Wang X, Li W, Niu C, Pan L, Li N, Li J. Thymosin alpha 1 is associated with improved cellular immunity and reduced infection rate in severe acute pancreatitis patients in a double-blind randomized control study. Inflammation. 2011;34(3):198–202.
Wolf E, Milazzo S, Boehm K, Zwahlen M, Horneber M. Thymic peptides for treatment of cancer patients. Cochrane Database Syst Rev. 2011;2011(2):Cd003993.
Wu J, Zhou L, Liu J, Ma G, Kou Q, He Z, Chen J, Ou-Yang B, Chen M, Li Y, et al. The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial. Crit Care. 2013;17(1):R8.
Zhang Y, Chen H, Li YM, Zheng SS, Chen YG, Li LJ, Zhou L, Xie HY, Praseedom RK. Thymosin alpha1- and ulinastatin-based Immunomodulatory strategy for sepsis arising from intra-abdominal infection due to carbapenem-resistant bacteria. J Infect Dis. 2008;198(5):723–30.
Zhang Y, Xia D, Li L, Gu Y, Shi L, Ma C, et al. Thymosin α1 alleviates lung injury in sepsis rats via Notch signaling pathway. Panminerva Med. 2023;65(3):413–14.
Ji SM, Li LS, Sun QQ, Chen JS, Sha GZ, Liu ZH. Immunoregulation of thymosin alpha 1 treatment of cytomegalovirus infection accompanied with acute respiratory distress syndrome after renal transplantation. Transpl Proc. 2007;39(1):115–9.
DÃaz-Lagares C, Pérez-Alvarez R, GarcÃa-Hernández FJ, Ayala-Gutiérrez MM, Callejas JL, MartÃnez-Berriotxoa A, Rascón J, Caminal-Montero L, Selva-O’Callaghan A, Oristrell J, et al. Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label. Arthritis Res Ther. 2011;13(4):R112.
Braga M, Costantini E, Di Francesco A, Gianotti L, Baccari P, Di Carlo V. Impact of thymopentin on the incidence and severity of postoperative infection: a randomized controlled trial. Br J Surg. 1994;81(2):205–8.
Li J, Liu CH, Wang FS. Thymosin alpha 1: biological activities, applications and genetic engineering production. Peptides. 2010;31(11):2151–8.
Vaziri ND, Pahl MV, Crum A, Norris K. Effect of uremia on structure and function of immune system. J Ren Nutr. 2012;22(1):149–56.
Yoon JW, Gollapudi S, Pahl MV, Vaziri ND. Naive and central memory T-cell lymphopenia in end-stage renal disease. Kidney Int. 2006;70(2):371–6.
Litjens NH, Huisman M, van den Dorpel M, Betjes MG. Impaired immune responses and antigen-specific memory CD4 + T cells in Hemodialysis patients. J Am Soc Nephrol. 2008;19(8):1483–90.
Sharif MR, Chitsazian Z, Moosavian M, Raygan F, Nikoueinejad H, Sharif AR, Einollahi B. Immune disorders in Hemodialysis patients. Iran J Kidney Dis. 2015;9(2):84–96.
Abbas AK, Trotta E, Marson DRS, Bluestone A. JA: Revisiting IL-2: biology and therapeutic prospects. Sci Immunol 2018;3(25).
He J, Zhang X, Wei Y, Sun X, Chen Y, Deng J, Jin Y, Gan Y, Hu X, Jia R, et al. Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus. Nat Med. 2016;22(9):991–3.
Wu L, Luo PP, Tian YH, Chen LY, Zhang YL. Clinical efficacy of thymosin alpha 1 combined with multi-modality chemotherapy and its effects on immune function of patients with pulmonary tuberculosis complicated with diabetes. Pak J Med Sci. 2022;38(1):179–84.
Hu X, Zhao M, Wang Y, Wang Y, Zhao S, Wu J, Li X, Peng S. Tetrahydro-β-carboline-3-carboxyl-thymopentin: a nano-conjugate for releasing pharmacophores to treat tumor and complications. J Mater Chem B. 2016;4(8):1384–97.
Ding JH, Wang LL, Chen Z, Wang J, Yu ZP, Zhao G, Chen BA. The role of Tα1 on the infective patients after hematopoietic stem cell transplantation. Int J Hematol. 2013;97(2):280–3.
Leichtling KD, Serrate SA, Sztein MB. Thymosin alpha 1 modulates the expression of high affinity interleukin-2 receptors on normal human lymphocytes. Int J Immunopharmacol. 1990;12(1):19–29.
Oncel M, Akbulut S, Toka Ozer T, Kiyici A, Keles M, Baltaci B, Turk S. Cytokines, adipocytokines and inflammatory markers in patients on continuous ambulatory peritoneal dialysis and hemodialysis. Ren Fail. 2016;38(7):1071–5.
Li PK, Ng JK, McIntyre CW. Inflammation and peritoneal Dialysis. Semin Nephrol. 2017;37(1):54–65.
Viaene L, Behets GJ, Heye S, Claes K, Monbaliu D, Pirenne J, D’Haese PC, Evenepoel P. Inflammation and the bone-vascular axis in end-stage renal disease. Osteoporos Int. 2016;27(2):489–97.
Xiao J, Gong Y, Chen Y, Yu D, Wang X, Zhang X, Dou Y, Liu D, Cheng G, Lu S, et al. IL-6 promotes epithelial-to-mesenchymal transition of human peritoneal mesothelial cells possibly through the JAK2/STAT3 signaling pathway. Am J Physiol Ren Physiol. 2017;313(2):F310–8.
Liu D, Yu Z, Yin J, Chen Y, Zhang H, Fan X, Fu H, Wan B. Effect of Ulinastatin combined with thymosin alpha1 on sepsis: a systematic review and meta-analysis of Chinese and Indian patients. J Crit Care. 2017;39:285–7.
Jankowska M, Cobo G, Lindholm B, Stenvinkel P. Inflammation and Protein-Energy wasting in the uremic milieu. Contrib Nephrol. 2017;191:58–71.
Tian Y, Xie X, Xiang S, Yang X, Lin J, Zhang X, Shou Z, Chen J. Risk factors and outcomes of Early-Onset peritonitis in Chinese peritoneal Dialysis patients. Kidney Blood Press Res. 2017;42(6):1266–76.
Kalantar-Zadeh K, Don BR, Rodriguez RA, Humphreys MH. Serum ferritin is a marker of morbidity and mortality in Hemodialysis patients. Am J Kidney Dis. 2001;37(3):564–72.